Document is current
Any future updates will be listed below
-
Authors
Iacoboni, Gloria https://orcid.org/0000-0003-0805-9288
Barba, Pere https://orcid.org/0000-0001-7076-7969
Khvedelidze, Irma
Ngoya, Maud https://orcid.org/0000-0002-7810-6900
Corradini, Paolo https://orcid.org/0000-0002-9186-1353
Sesques, Pierre
Subklewe, Marion https://orcid.org/0000-0001-9154-9469
Gomes da Silva, Maria https://orcid.org/0000-0002-6993-2450
Crochet, Gilles https://orcid.org/0009-0002-4655-6488
Dybko, Jaroslaw https://orcid.org/0000-0003-3555-2887
Zeberio, Izaskun
Martin Garcia-Sancho, Alejandro https://orcid.org/0000-0001-6330-1028
van Meerten, Tom
Sanderson, Robin https://orcid.org/0000-0003-4915-2833
Glass, Bertram https://orcid.org/0000-0003-2583-6333
Sureda, Anna https://orcid.org/0000-0002-1238-6970
Dreger, Peter https://orcid.org/0000-0002-7429-8570
Hermine, Olivier
Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
- License Information
-
More Information
Article History
Received: 12 April 2026
Revised: 29 July 2026
Accepted: 11 August 2026
First Online: 18 August 2026
Ethics
Competing interests: G Iacoboni—Consulting: Autolus, Bristol-Myers Squibb, Kite/Gilead, Janssen, Miltenyi, AbbVie, MSD, Regeneron. Honoraria: AbbVie, AstraZeneca, BMS, Kite/Gilead, Miltenyi, Sobi, Roche, Lilly. Travel support: AbbVie, AstraZeneca, Kite/Gilead, Miltenyi, Roche. P Barba—Consultancy: Jazz Pharmaceuticals, Nektar, Pierre Fabre, Miltenyi Biomed, Novartis, Pfizer, BMS/Celgene—Support for attending meetings and/or travel: Kite/Gilead, Novartis, Pfizer—Advisory Board: Allogene, BMS/Celgene, Incyte, Pierre Fabre, Amgen, Kite/Gilead, Novartis, Miltenyi Biomed, Autolus, Nektar, Pfizer. P Corradini—Consulting: Bristol-Myeres Squibb, Kite/Gilead, Roche, BeOne, Janssen. Honoraria: Bristol-Myeres Squibb, Kite/Gilead, Roche, BeOne, Lilly, Sobi, Novartis. Travel support: AbbVie, AstraZeneca, Kite/Gilead, Roche, Novartis, BeONE. P Sesques: Honoraria from Novartis, Kite/Gilead, Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Roche, and Chugai. M Gomes da Silva—Research grants: AstraZeneca; Consulting: Roche, Janssen, Lilly, Decera Medica Education; Travel support: Kite/Gilead, Janssen, AbbVie, Roche. G Crochet—Consulting: Roche, Kite/Gilead, AbbVie, Incyte, BMS, Sobi, Janssen. Honoraria: Roche, Kite/Gilead, AbbVie, Incyte, BMS, Sobi, Janssen. Travel support: Kite/Gilead, Roche, Sobi A, Martín García-Sancho. Honoraria: AbbVie, AstraZeneca, BeOne, BMS, Gilead/Kite, Ideogen, Incyte, Janssen, Kyowa Kirin, Lilly, Regeneron, Roche, Sobi, Takeda. Consulting fees: AbbVie, AstraZeneca, BeOne, BMS, Genmab, Gilead/Kite, GSK, Janssen, Lilly, MSD, Regeneron, Roche, Sobi. R Sanderson—Honoraria: Kite/Gilead, Novartis. Travel support: Kite/Gilead, AstraZeneca. Medical education: Kite/Gilead, AbbVie. Adboard: Kite/Gilead, Autolus. A Sureda: Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, GenMab, Abbvie, Jazz Pharmaceuticals, Pierre Fabre; Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi, GenMab, Abbvie; Speaker’s Bureau: Takeda; Research Support: Takeda; Non-profit organizations: Presidency of the EBMT. P. Dreger: consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speaker honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. He is the current chairman of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT). A Bazarbachi: Speaker bureau or advisory board: Novartis, Roche, Sanofi, Jazz, Adienne, Astellas, Takeda, Hikma, Janssen, MSD, AbbVie, Pfizer, and Amgen. Research support: Novartis, Roche, Takeda, Janssen, Astellas, Biologix, Pfizer, and Amgen.
